GLP-1s aren't just weight-loss drugs. Emerging research on kidney disease, Alzheimer's, and addiction suggests they're becoming one of the most important drug classes in modern medicine.

Key Takeaways

  • GLP-1s are gut-derived hormones that regulate insulin, reduce appetite, and slow digestion. They work on receptors distributed throughout the brain and body.
  • Three generations of GLP-1 medications are now in use or in development: semaglutide (GLP-1 only), tirzepatide (GLP-1 + GIP), and retatrutide (GLP-1 + GIP + GRA). 
  • Exercise (particularly resistance training) is key to GLP-1 therapy. Without it, a significant portion of weight lost can come from lean muscle mass rather than from fat.
  • Emerging research provides promising data on GLP-1s in chronic kidney disease, Alzheimer's, addiction medicine, and cardiovascular health.
  • The clinical community is increasingly clear: GLP-1s aren't diet drugs. They're a new class of metabolic medicine with applications that are still being mapped.

GLP-1 stands for glucagon-like peptide-1. It’s a hormone produced naturally in the L-cells of your small intestine. It belongs to a class called incretins, which play a central role in blood sugar regulation and appetite.

When you eat, your gut releases GLP-1, signaling the pancreas to increase insulin production and decrease glucagon, the hormone that raises blood sugar. It slows gastric emptying so food moves through your system more gradually. And it binds to receptors in the brain to reduce appetite and increase satiety.

GLP-1 receptor agonists mimic this hormone and extend its effects. The result is better blood sugar control, meaningful appetite reduction, and significant weight loss for many patients.

Newer medications expand on this. Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide), which induces satiety independently by binding receptors in the hypothalamus. Retatrutide, which is still in development, adds a glucagon receptor agonist to the mix. This produces the most complex mechanism and the most pronounced metabolic effects seen in early trials.

These aren't just incremental updates. Each generation is a meaningfully different drug.

Why Exercise and Nutrition Aren’t Optional

Now we come to the part that doesn't always make it into the prescribing conversation.

GLP-1 medications are highly effective at reducing body weight. No doubt about that. But weight loss and fat loss aren't the same thing. Without resistance training, a significant portion of what patients lose can be lean muscle mass. Some studies suggest up to 25–40% of weight lost without exercise comes from muscle rather than fat. That has real consequences for metabolic health, bone density, and long-term functional strength.

The solution is simple but not always easy: pair GLP-1 therapy with a consistent resistance training program. Muscle is the primary site of glucose uptake in the body, so building and maintaining it amplifies the metabolic benefits of GLP-1 medication. Cardiorespiratory exercise compounds the cardiovascular advantages already associated with GLP-1 use.

Protein intake matters too. Because these medications significantly suppress appetite, it's easy to under-eat protein without realizing it. For patients on GLP-1 therapy, hitting deliberate protein targets is part of making the medication work as intended.

The best outcomes come from treating this as a three-part protocol: medication, structured movement, and nutritional support.

What the Research Is Revealing

At the 2025 A4M Spring Congress, Dr. Barbie Barrett of Stanford University presented a review of emerging data on GLP-1s in disease states well beyond weight management. Her framing was direct: GLP-1s save lives. And increasingly, the data is showing how.

Chronic kidney disease. Early data suggests GLP-1 medications may slow or halt the progression of chronic kidney disease. This is a significant finding, given how few therapeutic options exist for patients already experiencing renal decline.

Neurological health. Alzheimer's research is showing that GLP-1s may increase neuroplasticity. The same receptors that regulate appetite and metabolism also exist in the brain, and researchers are starting to understand what activation of those receptors means for neurodegeneration.

Addiction medicine. This one tends to surprise people. Early research is showing that GLP-1 medications can reduce compulsive behaviors, including alcohol and drug use. More research is needed, but the mechanism is plausible and the implications are significant.

Cardiovascular health. GLP-1 medications appear to increase nitric oxide production, supporting endothelial function and vasodilation. The cardiovascular benefits of GLP-1s were among the first established outside of diabetes management.

The key factor here is that GLP-1 receptors are distributed throughout the body, from brain and kidneys to heart and gut. Targeting them appears to have systemic effects that we're still mapping. 

This drug class arrived as a metabolic intervention and is turning out to be considerably more.

If you’re interested in learning more about GLP-1 therapy, or in speaking with one of our clinical pharmacists, please don’t hesitate to contact us.